Q1 FY27 earnings call · July 23, 2026

Anthem Biosciences Ltd Q1 FY27 Earnings Call: Secures 60% Order Book Visibility, Adds New Large Pharma Client

Cofacto ResearchPublished July 23, 20266 min read
Quick summary

Anthem Biosciences Ltd held its Q1 FY27 earnings call on July 21, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Soft Topline, Resilient Margins in Seasonally Weak Quarter

  • Consolidated revenue of Rs.418 crore — CRDMO segment contributed 81.5% (Rs.341 crore) and specialty ingredients contributed 18.5% (Rs.78 crore).
  • EBITDA of Rs.176 crore, margin 39.6% — includes other income of Rs.25 crore; margin improved year-on-year supported by cost focus and yield optimization.
  • PAT of Rs.120 crore, margin 27.1% — Profit Before Tax stood at Rs.145 crore; net cash position as of 30 Jun 2026 was Rs.1,720 crore.
  • Revenue declined ~25% YoY — driven by timing shifts in customer deliveries, with a higher concentration scheduled in the second half of FY 2026-2027.
  • Q1 guided as softest quarter of FY 2026-2027 — management expects sequential growth from Q2 FY 2026-2027 onward; volatility deemed inherent to the business.
  • Specialty ingredients segment faced supply chain pressures due to geopolitical factors — management expressed confidence in decent growth by end of FY 2026-2027.

60% Visibility Anchors Double-Digit Full-Year Outlook

  • 60% order book visibility after Q1 for FY 2026-2027 — covers the whole business, though primarily applies to the CDMO segment; specialty ingredients is a month-on-month B2B business.
  • At start of FY 2026-2027, management had 50% of the current year's order book in hand — confidence to achieve the remaining 50% through new client onboarding and existing client volume increases.
  • Remaining 40% of revenue expected from three sources — new client wins (including recently onboarded large pharma customers), existing customers increasing volumes, and positive clinical outcomes from biotech clients leading to new orders.
  • One new large pharma customer added in Q1 — significant revenue contribution expected in later quarters of FY 2026-2027; agreement not yet signed.
  • Existing large biotech customer acquired by a big pharma ~one month ago — impact not material for remainder of FY 2026-2027; "provides a foot in the door" with the acquirer.
  • Active pipeline of 100+ early-stage programs and 10 late-phase molecules — includes a couple of ADC molecules; 4 molecules commercialized in FY 2025-2026; late-phase assets are 18-24 months from commercialization.
  • Order book for FY 2026-2027 indicates growth vs prior sales from recently commercialized molecules — sizable supplies depend on market penetration of innovator launches and are expected to take a couple of years.

Unit 4 Buildout Positions for Next Growth Phase

  • Unit 1 utilization at 75-78% in Q1 FY 2026-2027 — custom synthesis, similar to FY 2025-2026 exit of 74%.
  • Unit 2 utilization at 50% — covers both custom synthesis (post 130 kiloliter expansion) and fermentation (across 140 kiloliters).
  • Unit 3 (Neo Anthem) utilization at 30-35% — up from ~15% in FY 2025-2026, driven by new projects in peptide synthesis and oncology manufacturing rather than production shifts.
  • Management expects all three units to reach optimum utilization within two years — deferred deliveries from Q1 provide confidence of improving utilization.
  • Unit 4 capex outlay of Rs.1,200 crore (Phase 1) — adds 365 kL custom synthesis, 100 kL fermentation, and a food/nutra plant; commissioning targeted by end of FY 2027-2028.
  • CAPEX of ~Rs.700 crore guided for FY 2026-2027 — split ~50-50 across FY 2026-2027 and FY 2027-2028; capex to remain elevated in FY 2027-2028 then decline.
  • Unit 4 capacity primarily targets 14 existing commercial molecules and 10 late-stage molecules — commercialization growth needs to materialize for absorption.

Cost Discipline Preserves Industry-High Margins

  • EBITDA margin expanded year-on-year in Q1 FY 2026-2027 — supported by disciplined cost focus, yield optimization, and employee productivity; management committed to sustaining revenue growth in line with long-term historical performance.
  • Material margin improved in Q1 FY 2026-2027 despite slower top-line growth — cost advantages from new technologies including flow chemistry and biocatalysis.
  • Employee cost rate of 18.8% in Q1 FY 2026-2027 — elevated due to lower revenue base; management guides full-year FY 2026-2027 employee cost rate of ~13%.
  • Other expenses guided at 9-10% of revenue for FY 2026-2027 — Q1 level consistent with this range; no one-time items in the quarter.
  • ESOP cost of Rs.9 crore for full-year FY 2026-2027 — down from Rs.16 crore in FY 2025-2026; expected to decline further to ~Rs.5 crore in FY 2027-2028.
  • Working capital normal in Q1 — receivables declined due to weaker revenue; inventory increased slightly in preparation for Q2 and Q3 deliveries.
  • Effective tax rate expected to normalize to ~25-25.5% for FY 2026-2027 — as subsidiary Neo Anthem is expected to reach breakeven and potentially become profitable this year.

Semaglutide Approval and Demand Reacceleration in H2

  • Semaglutide API awaiting CDSCO approval expected within a quarter or two — management expects approval "sometime this year" (FY 2026-2027), which is the first gate to enable domestic sales.
  • Sampling with major domestic players complete — customers are ready to proceed once regulatory approval is received; overseas customers sampled but company is "not currently targeting other markets".
  • Management reiterated "industry high" margins sustainable in FY 2026-2027 — citing 60% order book already secured and cost advantages from new technologies.
  • Customer deferments impacted Q1 but do not affect long-term demand — occur when customers destock after over-anticipating sales in specific geographies (China, Germany, France) or face delayed regulatory approvals in new markets.
  • Management advised evaluating results on a full-year, holistic basis — Ajay Bhardwaj assured the company will grow in FY 2026-2027 consistent with past performance, and cautioned that lumpiness in quarterly CDMO revenue is normal.
  • GLP-1 described as a "long-term robust opportunity" — but commercial supply of semaglutide API has not yet started; near-term revenue contribution is contingent on CDSCO approval timing.

Early AI Adoption with Focus on Differentiation

  • Management sees AI as an evolving landscape with "limited concrete use cases so far" — separating hype from reality; feedback from large pharma clients on their AI usage has been vague with no definitive patterns yet.
  • Near-term AI applications identified in quality assurance and manufacturing — automating document review in QA and optimizing manufacturing resource allocation.
  • AI-driven drug target discovery could create more work for Anthem — drug candidates still require lab production and development, potentially increasing demand for CDMO services.
  • Over the next three to four years, Anthem is actively seeking AI use cases — management aims "not to miss the opportunity as applications develop".
  • Customers value three factors when choosing Anthem over other CDMOs — keeping promises, innovation (helping create new IP), and regulatory compliance track record.
  • Hardest capability to preserve as Anthem scales is staying ahead of rapid industry evolution — lifecycle from specialty to commoditization is shrinking; management highlighted that "failure to sharpen tools and differentiate risks being left behind".

Ask about this

Ask Cofacto a question about this call. Answers cite filings and company data.

Companies on this page

Related

Share on X · LinkedIn · WhatsApp

Disclaimer: This earnings call summary is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.